Hanmi Pharmaceutical stock (KR7128940004): shares rally on $1.26 billion Eli Lilly licensing deal

Hanmi Pharmaceutical shares in South Korea climbed sharply on 06/01/2026 after the company signed a licensing agreement with Eli Lilly worth up to $1.26 billion for its GLP-2 analogue sonefpeglutide, reinforcing its position in the gastrointestinal and metabolic disease space.

Hanmi Pharmaceutical shares on the Korea Exchange advanced strongly on 06/01/2026 after the South Korea-based drug maker announced a major licensing deal with US group Eli Lilly for its long-acting GLP-2 analogue sonefpeglutide, with the agreement carrying a potential value of up to USD 1.26 billion according to a company press release and Korean media coverage on the same day.

Under the contract, Hanmi Pharmaceutical said it will receive an upfront payment of USD 75 million from Eli Lilly and may be eligible for up to an additional USD 1.185 billion in clinical development, regulatory and commercial milestone payments tied to the progress of sonefpeglutide, which is currently in global phase 2 development for short bowel syndrome, according to a 06/01/2026 company statement and a report carried by BioSpace.

Hanmi Pharmaceutical noted that Eli Lilly receives exclusive rights to develop, manufacture and commercialize sonefpeglutide outside South Korea, while Hanmi retains rights for its home market, and Hanmi will also be entitled to tiered royalties on net sales once the product is launched in ex-Korea territories, according to the same 06/01/2026 disclosures and specialist pharmaceutical news reports.

Local financial press in South Korea reported on 06/01/2026 that Hanmi Pharmaceutical shares rose by low double-digit percentages in early trading on the Korea Exchange in response to the announcement of the licensing agreement, highlighting that investors reacted positively to the combination of the USD 75 million upfront payment and the sizeable milestone and royalty potential attached to the collaboration with Eli Lilly.

According to South Korean business media summaries on 06/01/2026, the stock price move placed Hanmi Pharmaceutical among the stronger performers on the day in the domestic healthcare segment, underlining how strategic partnering with a large US pharmaceutical company can immediately influence sentiment around a mid-cap Korean biopharma name listed on the KRX.

The new transaction also builds on Hanmi Pharmaceutical's broader strategy of partnering late-stage or platform assets with global peers, as highlighted by analysts in Korean-language coverage on 06/01/2026, where the Eli Lilly agreement is framed as an important validation of Hanmi's peptide and long-acting drug delivery technologies in gastrointestinal and metabolic indications.

The licensing deal announcement underscores the importance of South Korea as Hanmi Pharmaceutical's home base and primary listing market, with the shares trading in Korean won on the Korea Exchange, and domestic investors reacting first to the news flow before international investors can access secondary trading lines in other jurisdictions.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Hanmi Pharm
• Sector/industry: Pharmaceuticals and biotechnology, specialty drugs
• Headquarters/country: Seoul, South Korea
• Core markets: South Korea and global partners for licensed assets
• Key revenue drivers: Prescription drugs for metabolic and endocrine diseases, oncology and gastrointestinal disorders, as well as milestone and royalty income from partnered pipeline assets
• Home exchange/listing venue: Korea Exchange (KRX) (ticker commonly traded as Hanmi Pharmaceutical)
• Trading currency: KRW

Hanmi Pharmaceutical: core business model

Hanmi Pharmaceutical focuses on discovering and developing innovative small molecules and biologics in areas such as metabolic disease, oncology and gastrointestinal disorders, while increasingly monetizing its research platforms through licensing agreements that generate upfront payments, milestones and royalties.

What banks and research houses say about Hanmi Pharmaceutical

No verified analyst coverage was identified at the time of publication.

Conclusion

The 06/01/2026 licensing deal with Eli Lilly for sonefpeglutide marks a financially meaningful milestone for Hanmi Pharmaceutical, combining an immediate USD 75 million cash inflow with the possibility of over USD 1.1 billion in additional milestones and future royalties tied to global commercialization.

While no detailed analyst opinions were identified at the time of publication, the strong share price reaction on the Korea Exchange suggests that market participants are reassessing the value of Hanmi Pharmaceutical's pipeline and partnership model in light of the agreement with a major US pharmaceutical company.

Investors will now likely monitor progress of the phase 2 program and subsequent regulatory steps for sonefpeglutide, as the timing and magnitude of milestone triggers and potential royalty streams from Eli Lilly will be key variables for Hanmi Pharmaceutical's medium-term earnings profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.